Open Access
Subscription Access
Open Access
Subscription Access
Targeting Omc-B of Chlamydia trachomatis for the Blinding Infection Trachoma using Phytochemicals from Calpurnia aurea and Abrus precatorius
Subscribe/Renew Journal
Blinding trachoma called trichiasis is the eye infection caused by the obligate bacterium Chlamydia trachomatis, which triggers the inflammatory process in the conjunctiva mucosa and is believed to be the prime step towards the development of scarring. Reoccurrence of infection lead the eyelids to turn inward which ultimately scar the cornea through the continuous scrape caused by eyelashes. Like leprosy, Guinea worm, lymphatic filariasis, onchocerciasis, etc, trachoma is one of the neglected tropical disease, although 540 million people are reported at risk in 55 countries and 84 million are already infected. Trachoma, being the eighth commonest blinding disease overall the world, become global burden in terms of both disability it causes and the economic costs. The World Health Organization (WHO) assembly led an alliance GET2020 (Alliance for Global Elimination of Blinding Trachoma by 2020), in order to eliminate the blinding trachoma by the year 2020, which in adoption by SAFE strategy actively participates based on four different components like surgery for trichiasis, antibiotics for infection, facial cleanliness and avail criteria to improve environmental factors to reduce transmission. Zithromax, an antibiotic is used for treating the infection, has a lot more side effects and the effect on recurrence is also uncertain. With the recent development in the field of science and technology, the present study utilizing the bioinformatics tools and software, aims at identifying a novel inhibitor from the plant source for the targets that involve in the pathogenicity of the organism.
Keywords
Trachoma, Eye Infection, Chlamydia trachomatis, OmcB, Calpurnia aurea and Abrus precatorius.
Subscription
Login to verify subscription
User
Font Size
Information
- Taylor HR. Trachoma in Asia- A disappearing scourge. Taiwan Journal of Ophthalmology. 2016; 6: 55-57.
- Gambhir M, Basanez MG, Burton MJ, Solomon AW, Bailey RL, Holland MJ, Blake IM, Donnelly CA, Jabr I, Mabey DC, Grassly NC. The development of an age-structured model for trachoma transmission dynamics, pathogenesis andcontrol. PLoS Neglected Tropical Disease. 2009; 3: 1-8.
- Kuper H, Solomon AW, Buchan J, Zondervan M, Foster A. A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infectious Disease. 2003; 3: 372-381.
- World Health Organization. Weekly Epidemiological Record. 2013; 24: 241-256.
- Stocks ME, Ogden S, Haddad D, Addiss DG, McGuire C, Freeman MC. Effect of water, sanitation and hygiene on the prevention of trachoma: A systematic review and meta-analysis. PLOS Medicine. 2014; 11(2): 1-29.
- Guerra LO. Boga JA. Suarez JF. Benitez CF. and. Vazquez F. Pathogenesis of Chlamydia trachomatis in Humans. In. Human Emerging and Re-emerging Infections: Bacterial and Mycotic infections. Vol. II, Edited by Sunit KS and John. Wiley & Sons Inc., 2016; 1st Ed: pp. 635.
- Newhall WJV. Biosynthesis and disulfide cross-linking of outer membrane components during the growth cycle of Chlamydia trachomatis. Infection and Immunity. 1987; 55:162–168.
- Wang J, Zhang Y, Lu C, Lei L, Yu P, Zhong G. A genome-wide profiling of the humoralimmune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans. The Journal of Immunology. 2010; 185:1670–1680.
- Gervassi AL, Grabstein KH, Probst P, Hess B, Alderson MR, Fling SP. Human CD8+ T cells recognize the 60-kDa cysteinerich outer membrane protein from Chlamydia trachomatis. The Journal of Immunology. 2004; 173:6905–6913.
- Manli Q, Gong S, Lei L, Liu Q, Zhong G. A Chlamydia trachomatis OmcB C-Terminal fragment is released into the host cell cytoplasm and is immunogenic in humans. Infection and Immunity. 2011; 79(6): 2193-2203.
- Alvesalo J, Vuorela H, Tammela P, Leinonen M, Saikku P, Vuorela P. Inhibitory effect of dietary phenolic compounds on Chlamydia pneumonia in cell cultures. Biochemical Pharmacology. 2006; 71: 735-741.
- Potroz MG, Cho NJ. Natural products for the treatment of trachoma and Chlamydia trachomatis. Molecules. 2015; 20: 4180-4203.
- Vuorela P, Leinonen M, Saikku P, Tammela P, Rauha JP, Wennberg T, Vuorela H. Natural Products in the Process of Finding New Drug Candidates. Current Medicinal Chemistry. 2004; 11: 1375-1389.
- Engels D. The Global Trachoma Mapping Project: A Catalyst for Progress against Neglected Tropical Diseases. Ophthalmic Epidemiology. 2016; 23(S1): 1-2.
- Malik Z, Jain K, Ravindran K, Sathiyaraj G. In vitro antimicrobial activity and preliminary phytochemical analysis of Berberis aristata. International Journal of Ethnobiology and Ethnomedicine. 2017; 4(1): 1-6.
- Sathishkumar R, Tharani R. In silico determination of efficiency of plant secondary metabolites to eradicate trachoma- A binding keratoconjuctivitis disease. Journal of Applied Pharmaceutical Science. 2017; 7(9): 116-121.
- Rautiainen S, Lindblad BE, Morgenstern R, Wolk A. Vitamin C supplements and the risk of age-related cataract: a populationbased prospective cohort study in women. American Journal of Clinical Nutrition. 2010; 91(2): 487-493.
- Tolchard J, Walpole SJ, Miles AJ, Maytum R, Eaglen LA, Hackstadt T, Wallace BA, Blumenschein TMA. The intrinsically disordered Tarp protein from Chlamydia binds actin with a partially preformed helix. Scientific Reports. 2018; 8: 1-11.
- Carabeo RA, Grieshaber SS, Fischer E, Hackstadt T. Chlamydia trachomatis induces remodeling of the actin cytoskeleton during attachment and entry into HeLa cells. Infection and Immunity. 2002; 70: 3793-3803.
Abstract Views: 176
PDF Views: 0